吉西他滨联合奥沙利铂治疗晚期胰腺癌的临床疗效观察  

Gemcitabine combined therapy with Oxaliplatin the clinical effect of the treatment of advanced pancreatic cancer

作　　者：郝灵芳[1] 院刚[2] 

机构地区：[1]呼和浩特市第一医院肿瘤科,内蒙古呼和浩特010030 [2]呼和浩特市第一医院放疗科

出　　处：《疾病监测与控制》2015年第4期238-238,237,共2页Journal of Diseases Monitor and Control

摘　　要：目的观察吉西他滨联合奥沙利铂组成的GEMOX方案治疗晚期胰腺癌的疗效。方法进展期胰腺癌40例,观察组应用吉西他滨(GEM)1 000mg/m2静滴半小时,d1,d8;奥沙利铂(OXA)85mg/m2静滴2h,d1。21d重复。至少接受2个周期的化疗,对照组采用吉西他滨单药。按照RESCIT标准进行评价。结果吉西他滨单药组完全缓解率5%(1/20),吉西他滨联合奥沙利铂组完全缓解率20%(4/20),吉西他滨单药组总有效率15%(3/20),吉西他滨联合奥沙利铂组总有效率35%(7/20);以上结果两组比较差异均有统计学意义(P<0.05)。两组近期不良反应相似。结论吉西他滨联合奥沙利铂组完全缓解率、总有效率明显提高,而其两组不良反应比较无明显差异。Objective Observation of gemcitabine combined GEMOX scheme of oxaliplatin the efficacy of the treatment of advanced pancreatic cancer. Methods Advanced pancreatic cancer 40 cases, observation group application gemcitabine （GEM） 1 000 mg/m2 static drop half an hour, dl, d8. （OXA） 85 rag/m2 oxaliplatin static drop 2 hours, dl, 21 days to repeat. Receive at least two cycles of chemotherapy, the control group using gemcitabine single-agent. According to the RESCIT standard evaluation. Results Gemcitabine single-agent set of complete response rate was 5% （1/20）, gemcitabine combined set of oxaliplatin complete remission rate was 20% （4/20）, gemcitabine single-agent group total effective rate 15% （3/20）, gemcitabine combined oxaliplatin group total effective rate 35% （7/20）; These results are similar between the two groups have statistical significance （P 〈 0.05）. Two groups of recent similar adverse reactions. Conclusion Gemcitabine combined set of oxaliplatin complete remission rate and total effective rate increased significantly, while the two groups of adverse reactions was no significant difference.

关 键 词：胰腺癌 晚期 吉西他滨 奥沙利铂 

分 类 号：R735[医药卫生—肿瘤]